Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
J Surg Oncol. 2014 Jun;109(8):818-22. doi: 10.1002/jso.23573. Epub 2014 Feb 13.
To investigate how location of positive surgical margins (PSM) in pT2 tumors affect the risk of biochemical recurrence (BR).
The study includes 1,133 consecutive patients from 1995 until end of 2011, who had organ-confined disease (pT2) following RP. The location of PSM was stratified into apical and non-apical. BR was defined as the first PSA ≥ 0.2 ng/ml after RP. Risk of BR was analyzed with Kaplan-Meier and Cox regression analysis.
Median follow-up was 3.6 years (range: 0.5-15.5 years). The overall pT2 PSM rate was 26.3%. Overall, a pT2 with PSM had a 3.1-fold increased risk of BR compared to margin negative patients. Patients with pT2 apical and non-apical PSM had a 5-year biochemical recurrence-free survival of 84.9% (95% CI: 77.6-92.2%) and 78.6% (95% CI: 71.3-85.9%), respectively. In multivariate analysis, pT2 apical and non-apical PSM was individually associated with a 2.2- and 3.8-fold increased risk of BR compared to margin negative patients.
In our cohort the location of pT2 PSM was associated with time to BR, that is, patients with non-apical pT2 PSM endured the highest risk of BR compared to apical PSM. This may indicate that not all patients with pT2 PSM should be offered adjuvant therapy.
研究 pT2 肿瘤中的阳性切缘(PSM)位置如何影响生化复发(BR)的风险。
本研究纳入了 1995 年至 2011 年底期间的 1133 例连续患者,这些患者在接受 RP 后患有局限性疾病(pT2)。PSM 的位置分为 apical 和 non-apical。BR 定义为 RP 后首次 PSA≥0.2ng/ml。采用 Kaplan-Meier 和 Cox 回归分析评估 BR 的风险。
中位随访时间为 3.6 年(范围:0.5-15.5 年)。总体 pT2 PSM 率为 26.3%。总体而言,与边缘阴性患者相比,有 PSM 的 pT2 患者发生 BR 的风险增加了 3.1 倍。pT2 apical 和 non-apical PSM 的患者 5 年生化无复发生存率分别为 84.9%(95%CI:77.6-92.2%)和 78.6%(95%CI:71.3-85.9%)。多变量分析显示,与边缘阴性患者相比,pT2 apical 和 non-apical PSM 分别与 BR 风险增加 2.2 倍和 3.8 倍相关。
在我们的队列中,pT2 PSM 的位置与 BR 时间相关,即与 apical PSM 相比,non-apical pT2 PSM 的患者发生 BR 的风险最高。这可能表明并非所有 pT2 PSM 的患者都应接受辅助治疗。